Discovery Pipeline

CTx advances promising targets by committing the full suite of infrastructure equipment and skills to the three phases of early drug discovery and development – hit discovery, lead generation and lead optimisation.

process2

 

Our Pipeline

Commercialised
Focal Adhesion Kinase
FAK inhibitors have potential utility in various cancer types to reduce cancer stem cell burden, primary tumour growth and reduction of metastatic disease (alone and in combination with current anti-cancer therapeutic regimens) including cancers of high unmet need known to be enriched for cancer stem cells or merlin-negative cancers.

Licensed to CRT UK
FAK/VEGFR3/FLT3
Triple kinase inhibitor, targeting focal adhesion kinase (FAK), vascular endothelial growth factor receptor 3 (VEGFR3) and FMS-like Tyrosine kinase-3 (FLT3), has potential utility in various cancer types to reduce cancer stem cell burden, primary tumour growth and reduction of metastatic disease (alone and in combination with current anti-cancer therapeutic regimens) including cancers of high unmet need known to be enriched for cancer stem cells or merlin-negative cancers. FAK-FLT3-VEGFR3 inhibitors also have potential utility in FLT3-driven and FAK-positive or FAK splice-variant-positive AML.

Licensed to CRT UK
VEGFR3
Inhibition of vascular endothelial growth factor receptor-3 (VEGFR3) promises to prevent peritumoural lymphangiogenesis, lymph node metastasis and, possibly, proliferation of lymphatic vessels.

Licensed to Bionomics
PRMT5
PRMT5 is an epigenetic target with cancer and non-cancer clinical potential (e.g. melanoma, mantle cell lymphoma, breast, β-thalassemia, sickle cell disease). CTx has identified two novel series of PRMT5 small molecule inhibitors with excellent development potential. Biochemical, in vitro and in vivo models are in place and there is an established collaboration with a world leading PRMT5 research group.

Licensed to CRT UK
Pan-Kinase Inhibitor ( Research Tool )
A pan-kinase affinity molecule jointly discovered and developed by CTx and the Garvan Institute of Medical Research has been licensed to SYNkinase Pty Ltd. This compound is of great value as a research and diagnostic tool to screen human cells and tissues and identify potential drug targets in diseased states.

Licensed to SYNkinase
Lead Optimisation
Novel antimitotic
Information about this program is confidential at this time

SmallTumour Confidential

 

 

Lead Generation
MOZ
Inhibition of the epigenetic regulator, Monocytic leukaemia zinc finger (MOZ) will be of therapeutic benefit in AML

AML
Hit Discovery
PRMTs (3)
CTx is building on its expertise with Protein Arginine Methyltransferase-5 (PRMT5) and is conducting HTCS campaigns against other members of this protein family known to be involved in the epigenetic regulation of several cancers.
Paediatric (3)
CTx is running High Throughput Content Screening campaigns against three targets known to be play a role in paediatric cancers.